We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.25 | 10.00 | 10.50 | 10.25 | 10.25 | 10.25 | 239,636 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.95 | 95.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/8/2017 07:08 | A nature of a bb is determined by the people who post. It will only be different if the posters change - that includes you! | gazza | |
14/8/2017 07:05 | Aw, you miss me already!!! | chelsea34 | |
14/8/2017 06:57 | Interesting/sad to see this BB turning into LSE.... hehe It seems that everything is different but nothing has changed! ATB | oldnotwise | |
14/8/2017 05:57 | An interesting link posted by Gee Cee yesterday on LSE................. hxxp://fortune.com/2 Especially to those who write off our data as inconclusive. Risk/Reward!!!! | chelsea34 | |
14/8/2017 05:28 | Thanks Aimbig, been up all night, registered and cant log back in!!! So will call there support line a bit later. Halfway through Q3, 9/10 weeks till AGM, five weeks till confirmation of same. First day back for many returness from holiday, share price attractive for some.And boy do we need to see some good buying, seller around again, lets hope not for long. Does anyone really think we won"t get definitive news by the AGM??? Intending to attend it, a longshot though, catching JC for a few minutes last year he assured me we will be a very different company by next years AGM!!!! We shall soon find out. ATB | chelsea34 | |
13/8/2017 19:28 | BS, never did like the posting format over here, sure it is easier than i am finding it too lol. How many are showing duplicate or triplicate?? Just looking for some worthwhile debate, unfortunately on LSE it was getting harder to find and none too pleased with ADMIN these days, why not just remove the personal posts whoever they are from, would soon change things for the better?? Also looking for a new level 2, £45 seems a bit hefty compared to the £20 over there. | chelsea34 | |
13/8/2017 18:43 | Chelsea, Was just joking as your posts seem to be posted in duplicate and triplicate. Thank goodness it's yours rather than mine and Inanaco's! | bermudashorts | |
13/8/2017 18:37 | Boom, lol, I know you know , just saying how i feel it is, not withstanding I am still long. Agree with Smiler there, another reason why investor confidence is low. Happy to have new iis on board, especially L & G with 5.3%. We know what news we need to act as a catalyst for an share price recovery, at this level would rather be in than out for sure, Haven"t topped up here all year, will be happy to see 26p again lol for now, good news,??? well it is possible, not so sure the science will be left to rot on any shelf. | chelsea34 | |
13/8/2017 17:25 | Hi Boom, i did not agree or disagree with you on if a Dr would or would not prescribe it off label I would not know i am not a Dr ... just reasoning that he potentially could that was all ... | inanaco | |
13/8/2017 17:12 | Smiler, Agree - | bermudashorts | |
13/8/2017 17:11 | Chelsea, Are you trolling this board with negative posts? lol | bermudashorts | |
13/8/2017 17:11 | On or Off label matters not one jot. What does matter is how Scancell get to that stage. With their past performances of cash calls all it can lead to is dilution at a significant reduction to current SP | wanderer1210_0 | |
13/8/2017 17:10 | Inanaco Honestly, please read what I actually post. Whether or not it could be prescribed off label has never been in question. It's whether doctors actually would - see my 10336. I also think we need to be careful about raising expectations that approval in combination could lead to sales in the adjuvant setting. We disagree on that. That's absolutely fine and like most things we disagree on, I really hope that I'm wrong and you're right. | bermudashorts | |
13/8/2017 17:05 | On saying that, as i felt last Monday we did see some half decent buying at 10.50 last week, only for another tranche of selling to keep the downward pressure on and again lead to periods where selling was reduced to 100 shares as the week before. Just hoping this tranche doesn"t have the legs that the Helium one had. Evidence too that PIs are not jumping in at 10.50, as I have said confidence is low, promises of inflection breaking news have not transpired, PIs are prepared to pay more according to news. Another interesting week ahead. | chelsea34 | |
13/8/2017 17:05 | On saying that, as i felt last Monday we did see some half decent buying at 10.50 last week, only for another tranche of selling to keep the downward pressure on and again lead to periods where selling was reduced to 100 shares as the week before. Just hoping this tranche doesn"t have the legs that the Helium one had. Evidence too that PIs are not jumping in at 10.50, as I have said confidence is low, promises of inflection breaking news have not transpired, PIs are prepared to pay more according to news. Another interesting week ahead. | chelsea34 | |
13/8/2017 16:50 | thanks boom .... my original post nanaco13 Aug '17 - 12:32 - 10317 of 10360 0 0 Edit Now lets say Scancell achieved approval for the Combo ... not sure exactly how this would work, but the data set for Mono SCib1 could allow it to be used in the adjuvant setting Why might an approved drug be used for an unapproved use? From the FDA perspective, once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient. You may be asking yourself why your healthcare provider would want to prescribe a drug to treat a disease or medical condition that the drug is not approved for. One reason is that there might not be an approved drug to treat your disease or medical condition. Another is that you may have tried all approved treatments without seeing any benefits. In situations like these, you and your healthcare provider may talk about using an approved drug for an unapproved use to treat your disease or medical condition. | inanaco | |
13/8/2017 16:47 | Yes of course it could be prescribed off label - ???? lol we have come full circle. Catch you later. | bermudashorts | |
13/8/2017 16:41 | thanks boom if its two treatments then .... scib1 would require an approved license for use as a drug ... so it could be prescribed off label c7 posted the same post twice ... i am not engaging him at all only the highlighted text in Scancells case it goes way deeper just refining his post to remove any confusion as to what is combined ... | inanaco | |
13/8/2017 16:31 | "I just hope you appreciate they are two different treatments that function in completely different ways which produce a combined synergy effect" Thanks for the heads up but I had picked that up from my research. I don't know why you have such an issue with the wording 'combined with' or why you have pulled Chelsea up on it - Scancell use it all the time. Nobody has ever suggested that it's combined with the PD-1 before administration. | bermudashorts | |
13/8/2017 16:30 | On saying that, as i felt last Monday we did see some half decent buying at 10.50 last week, only for another tranche of selling to keep the downward pressure on and again lead to periods where selling was reduced to 100 shares as the week before. Just hoping this tranche doesn"t have the legs that the Helium one had. Evidence too that PIs are not jumping in at 10.50, as I have said confidence is low, promises of inflection breaking news have not transpired, PIs are prepared to pay more according to news. Another interesting week ahead. | chelsea34 | |
13/8/2017 16:13 | C7 ""for use when combined with Keytruda"" they don't combine the drugs ..... | inanaco | |
13/8/2017 16:10 | Bermuda, therein lies the frustration of all LTHs. I also don"t blame Scancell for the delay we have endured awaiting manufacture of the new vaccine. Can"t imagine any small biotech on the AIM market having £1m of shareholders money tied up in new vaccine ""in the event of"", as we have seen. The need to get SCIB1 into the trial with Keytruda and gain approval ""for use when combined with Keytruda"" will only bring in the sort of investment we need to prove up Immunobody further as a mono therapy for treatment in early detection cancers long before stage 4 diagnosis. Nobody knows what will be declared by the BOD by the AGM, and further down the road. Again at just over 10p on the ask ,risk/reward makes this a very interesting play. | chelsea34 | |
13/8/2017 16:10 | Scancell has it spot on .... its a combination treatment, its a combination trial what its not is a combined drug to form a single drug delivery | inanaco | |
13/8/2017 16:07 | ... happy to leave it anyway i do have things to do ... I just hope you appreciate they are two different treatments that function in completely different ways which produce a combined synergy effect | inanaco |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions